Doxycycline and Minocycline Drugs as a Treatment Proposal for Inhibition of ARDS and Inflammatory Cytokines of SARS-CoV-2 | ||||
| Al-Azhar University Journal of Virus Researches and Studies | ||||
| Article 1, Volume 2, Issue 1, 2020, Page 1-7 PDF (328.11 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/AUJV.2020.106725 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Mohamed A. Mostafa
| ||||
| Faculty of Pharmacy, Mansoura University. | ||||
| Abstract | ||||
| The novel coronavirus 2 (COVID 19) is a highly transmittable viral disease aroused in Wuhan, China at the end of 2019 and spreads round the world. The International Committee on Taxonomy of Viruses (ICTV) named it on February 11, 2020, as severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). SARS-CoV-2 can infect humans as well likewise as animals and transmit from person to person. The World Health Organization declared that the novel coronavirus 2 pneumonia epidemic and was classified as a public health emergency of international attention on January 30, 2020. When COVID-19 infects the upper and lower respiratory tract it can give rise to mild or acute respiratory syndrome with resultant release of cytokines like IL-1B, IL6, IL37, TNF alpha and CCL2. we evaluated the effectiveness of doxycycline and minocycline as a tetracycline derivative to modulate serum levels of cytokines and we stand out their anti- inflammatory effect that can inhibit inflammation and pro-inflammation response that were caused by COVID-19, providing pertinent strategy. | ||||
| Keywords | ||||
| COVID-19; SARS-CoV-2; ARDS; Tetracyclines; Cytokines | ||||
|
Statistics Article View: 267 PDF Download: 277 |
||||
